Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of

Kazutaka Fukumura1, Prit Benny Malgulwar1, Grant M Fischer1,2,3

  • 1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Acta Neuropathologica
|January 4, 2021
PubMed

Insights

Brain metastasis (BM) involves shared biological mechanisms across cancers. Studies reveal impaired immunity, increased oxidative phosphorylation, and altered signaling pathways characterize BM, suggesting new therapeutic targets.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Pathology

Background:

  • Brain metastasis (BM) is a severe complication of systemic cancers.
  • Understanding shared mechanisms driving BM is crucial for developing effective therapies.

Purpose of the Study:

  • To identify and characterize the biological mechanisms underlying brain metastasis.
  • To investigate genomic, transcriptional, and proteomic profiles of brain metastatic tumors.

Main Methods:

  • Genomic, transcriptional, and proteomic profiling (whole-exome sequencing, mRNA-seq, RPPA).
  • Analysis of lung, breast, and renal cell carcinomas with BM and matched controls.
  • Multiplexed immunofluorescence and in vitro/in vivo functional studies.

Main Results:

  • No specific genomic alterations linked to BM.
  • Correlations found with impaired cellular immunity, upregulated oxidative phosphorylation (OXPHOS), and PI3K signaling.
  • BM tissues showed T cell depletion and heightened oxidative metabolism, with sensitivity to OXPHOS inhibition.

Conclusions:

  • Pathophysiological rewiring of signaling, metabolism, and immune microenvironment characterizes BM.
  • These shared alterations offer potential therapeutic targets for diverse systemic cancers with BM.

Related Concept Videos